NAV

Ezeprogind

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ezeprogind
DrugBank Accession Number
DB16954
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 428.669
Monoisotopic: 428.362745441
Chemical Formula
C25H44N6
Synonyms
  • 1,4-piperazinedipropanamine, n'-1h-benzimidazol-2-yl-n,n-bis(2-methylpropyl)-
  • 1,4-piperazinedipropanamine, n4-1h-benzimidazol-2-yl-n1,n1-bis(2-methylpropyl)-
  • Azp-2006 free base
  • Azp2006 free base
  • N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo(d)imidazol-2-amine
  • N4-1h-benzimidazol-2-yl-n1,n1-bis(2-methylpropyl)-1,4-piperazinedipropanamine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Ezeprogind disulfate7L8UKH84T01616671-13-6GIYBNVHXNIZNBZ-UHFFFAOYSA-N

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
TR9YQ07ELN
CAS number
615539-20-3
InChI Key
KLKKWCPJBTXWOV-UHFFFAOYSA-N
InChI
InChI=1S/C25H44N6/c1-21(2)19-31(20-22(3)4)14-8-13-30-17-15-29(16-18-30)12-7-11-26-25-27-23-9-5-6-10-24(23)28-25/h5-6,9-10,21-22H,7-8,11-20H2,1-4H3,(H2,26,27,28)
IUPAC Name
N-[3-(4-{3-[bis(2-methylpropyl)amino]propyl}piperazin-1-yl)propyl]-1H-1,3-benzodiazol-2-amine
SMILES
CC(C)CN(CCCN1CCN(CCCNC2=NC3=CC=CC=C3N2)CC1)CC(C)C

References

General References
Not Available
ChemSpider
8427495
BindingDB
50134471
ChEMBL
CHEMBL419432
ZINC
ZINC000027209228

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentProgressive Supranuclear Palsy (PSP)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0779 mg/mLALOGPS
logP4.37ALOGPS
logP3.75Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.45Chemaxon
pKa (Strongest Basic)10.95Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area50.43 Å2Chemaxon
Rotatable Bond Count13Chemaxon
Refractivity133.94 m3·mol-1Chemaxon
Polarizability54.54 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 14, 2022 21:36 / Updated at December 13, 2022 10:46